USP11 is a promising therapeutic target in T-ALL, as it controls the lymphocyte-specific kinase (LCK) activity downstream of the T-cell receptor (TCR) signaling pathway, blocking the activation of the glucocorticoid receptor (GR) upon application of glucocorticoids in T-ALL [5]. Here, NR3C1 is linked to acute lymphoblastic leukemia.